1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Generic Name | Common Trade Name(s) | Classification | Date Marketed in Canada (yyyy/mm/dd) |
---|---|---|---|
Baloxavir marboxil | Xofluza | Antiviral agent | 2020/02/19 |
Baricitinib | Olumiant | Immunosuppressant | 2018/08/17 |
Belimumab | Benlysta | Immunosuppressant | 2011/10/01 |
Bendamustine | Treanda | Antineoplastic agent | 2012/09/12 |
Benralizumab | Fasenra | Respiratory agent | 2018/03/28 |
Benzocaine | Orajel teething products | 2018/05/23 | |
Besifloxacin | Besivance | Fluoroquinolone | 2010/01/27 |
Betamethasone valerate | Beteflam | Anti-inflammatory agent | 2016/04/05 |
Bilastine | Blexten | Antihistamine | 2016/12/02 |
Boceprevir | Victrelis | Hepatitis C virus protease inhibitor | 2011/07/29 |
Brexpiprazole | Rexulti | Antipsychotic agent | 2017/04/20 |
Brigatinib | Alunbrig | Antineoplastic agent | 2018/07/26 |
Brimonidine | Onreltea | alpha-2 adrenergic receptor antagonist for rosacea | 2014/04/23 |
Brivaracetam | Brivlera | Antiepileptic agent | 2016/05/10 |
Brolucizumab | Beovu | Antineovascularisation agent | 2020/05/15 |
Buprenorphine | BuTrans | Opioid analgesic | 2010/03/05 |
Buprenorphine | Belbuca | Opioid analgesic | 2018/01/17 |
Buprenorphine | Probuphine | Opiate partial agonist | 2018/04/18 |
Buprenorphine | Sublocade | Partial opioid agonist | 2019 |
Burosumab | Crysvita | Fibroblast growth factor 23 (FGF23) Inhibitor | 2018/12/05 |